177 related articles for article (PubMed ID: 32725966)
21. Potent anti-tumour activity of a novel conditionally replicating adenovirus for melanoma via inhibition of migration and invasion.
Jiang G; Yang CS; Xu D; Sun C; Zheng JN; Lei TC; Liu YQ
Br J Cancer; 2014 May; 110(10):2496-505. PubMed ID: 24714752
[TBL] [Abstract][Full Text] [Related]
22. Development of an optimized conditionally replicative adenoviral agent for ovarian cancer.
Zhu ZB; Lu B; Park M; Makhija SK; Numnum TM; Kendrick JE; Wang M; Tsuruta Y; Fisher P; Alvarez RD; Zhou F; Siegal GP; Wu H; Curiel DT
Int J Oncol; 2008 Jun; 32(6):1179-88. PubMed ID: 18497979
[TBL] [Abstract][Full Text] [Related]
23. Combination with low-dose gemcitabine and hTERT-promoter-dependent conditionally replicative adenovirus enhances cytotoxicity through their crosstalk mechanisms in pancreatic cancer.
Onimaru M; Ohuchida K; Nagai E; Mizumoto K; Egami T; Cui L; Sato N; Uchino J; Takayama K; Hashizume M; Tanaka M
Cancer Lett; 2010 Aug; 294(2):178-86. PubMed ID: 20163915
[TBL] [Abstract][Full Text] [Related]
24. 5/35 fiber-modified conditionally replicative adenovirus armed with p53 shows increased tumor-suppressing capacity to breast cancer cells.
He X; Liu J; Yang C; Su C; Zhou C; Zhang Q; Li L; Wu H; Liu X; Wu M; Qian Q
Hum Gene Ther; 2011 Mar; 22(3):283-92. PubMed ID: 20846024
[TBL] [Abstract][Full Text] [Related]
25. Conditionally replicative adenovirus driven by the human telomerase promoter provides broad-spectrum antitumor activity without liver toxicity.
Irving J; Wang Z; Powell S; O'Sullivan C; Mok M; Murphy B; Cardoza L; Lebkowski JS; Majumdar AS
Cancer Gene Ther; 2004 Mar; 11(3):174-85. PubMed ID: 14726958
[TBL] [Abstract][Full Text] [Related]
26. A novel apoptotic mechanism of genetically engineered adenovirus-mediated tumour-specific p53 overexpression through E1A-dependent p21 and MDM2 suppression.
Yamasaki Y; Tazawa H; Hashimoto Y; Kojima T; Kuroda S; Yano S; Yoshida R; Uno F; Mizuguchi H; Ohtsuru A; Urata Y; Kagawa S; Fujiwara T
Eur J Cancer; 2012 Sep; 48(14):2282-91. PubMed ID: 22244827
[TBL] [Abstract][Full Text] [Related]
27. Antitumor Effects of Oncolytic Adenovirus-Carrying siRNA Targeting Potential Oncogene EphA3.
Zhao Y; Li H; Wu R; Li S; Wang P; Wang H; Wang J; Zhou J
PLoS One; 2015; 10(5):e0126726. PubMed ID: 25978371
[TBL] [Abstract][Full Text] [Related]
28. Eliminating established tumor in nu/nu nude mice by a tumor necrosis factor-alpha-related apoptosis-inducing ligand-armed oncolytic adenovirus.
Dong F; Wang L; Davis JJ; Hu W; Zhang L; Guo W; Teraishi F; Ji L; Fang B
Clin Cancer Res; 2006 Sep; 12(17):5224-30. PubMed ID: 16951242
[TBL] [Abstract][Full Text] [Related]
29. Analysis of adenovirus trans-complementation-mediated gene expression controlled by melanoma-specific TETP promoter in vitro.
Fontecedro AC; Lutschg V; Eichhoff O; Dummer R; Greber UF; Hemmi S
Virol J; 2010 Jul; 7():175. PubMed ID: 20670430
[TBL] [Abstract][Full Text] [Related]
30. Vascular endothelial growth factor promoter-based conditionally replicative adenoviruses effectively suppress growth of malignant pleural mesothelioma.
Harada A; Uchino J; Harada T; Nakagaki N; Hisasue J; Fujita M; Takayama K
Cancer Sci; 2017 Jan; 108(1):116-123. PubMed ID: 27783867
[TBL] [Abstract][Full Text] [Related]
31. Treatment of metastatic renal cancer with capsid-modified oncolytic adenoviruses.
Guse K; Ranki T; Ala-Opas M; Bono P; Särkioja M; Rajecki M; Kanerva A; Hakkarainen T; Hemminki A
Mol Cancer Ther; 2007 Oct; 6(10):2728-36. PubMed ID: 17938266
[TBL] [Abstract][Full Text] [Related]
32. E1A- and E1B-Double mutant replicating adenovirus elicits enhanced oncolytic and antitumor effects.
Kim J; Kim JH; Choi KJ; Kim PH; Yun CO
Hum Gene Ther; 2007 Sep; 18(9):773-86. PubMed ID: 17725410
[TBL] [Abstract][Full Text] [Related]
33. Cancer-specific targeting of a conditionally replicative adenovirus using mRNA translational control.
Stoff-Khalili MA; Rivera AA; Nedeljkovic-Kurepa A; DeBenedetti A; Li XL; Odaka Y; Podduturi J; Sibley DA; Siegal GP; Stoff A; Young S; Zhu ZB; Curiel DT; Mathis JM
Breast Cancer Res Treat; 2008 Mar; 108(1):43-55. PubMed ID: 17508279
[TBL] [Abstract][Full Text] [Related]
34. Dendritic cell-based immunotherapy in prevention and treatment of renal cell carcinoma: efficacy, safety, and activity of Ad-GM·CAIX in immunocompetent mouse models.
Birkhäuser FD; Koya RC; Neufeld C; Rampersaud EN; Lu X; Micewicz ED; Chodon T; Atefi M; Kroeger N; Chandramouli GV; Li G; Said JW; McBride WH; Kabbinavar FF; Ribas A; Pantuck AJ; Belldegrun AS; Riss J
J Immunother; 2013 Feb; 36(2):102-11. PubMed ID: 23377663
[TBL] [Abstract][Full Text] [Related]
35. A novel oncolytic adenovirus targeting Wnt signaling effectively inhibits cancer-stem like cell growth via metastasis, apoptosis and autophagy in HCC models.
Zhang J; Lai W; Li Q; Yu Y; Jin J; Guo W; Zhou X; Liu X; Wang Y
Biochem Biophys Res Commun; 2017 Sep; 491(2):469-477. PubMed ID: 28698142
[TBL] [Abstract][Full Text] [Related]
36. Intratumor injection of oncolytic adenovirus expressing HSP70 prolonged survival in melanoma B16 bearing mice by enhanced immune response.
Ren Z; Ye X; Fang C; Lu Q; Zhao Y; Liu F; Liang M; Hu F; Chen HZ
Cancer Biol Ther; 2008 Feb; 7(2):191-95. PubMed ID: 18073525
[TBL] [Abstract][Full Text] [Related]
37. Potent antitumor efficacy of interleukin-18 delivered by conditionally replicative adenovirus vector in renal cell carcinoma-bearing nude mice via inhibition of angiogenesis.
Zheng JN; Pei DS; Sun FH; Liu XY; Mao LJ; Zhang BF; Wen RM; Xu W; Shi Z; Liu JJ; Li W
Cancer Biol Ther; 2009 Apr; 8(7):599-606. PubMed ID: 19305163
[TBL] [Abstract][Full Text] [Related]
38. The antitumor efficacy of IL-24 mediated by E1A and E1B triple regulated oncolytic adenovirus.
Xiao LL; Wu YM; Qian J; Tan Y; Xie GL; Zhang KJ; Wang YG; Jia XY; Liu XY
Cancer Biol Ther; 2010 Aug; 10(3):242-50. PubMed ID: 20574150
[TBL] [Abstract][Full Text] [Related]
39. A novel CRAd in combination with cisplatin enhanced the antitumor efficacy in ovarian cancer.
Zhang B; Liu Y; Zhang P; Wei Y; Yin X; Zheng J
Int J Gynecol Cancer; 2011 Dec; 21(9):1540-6. PubMed ID: 22080895
[TBL] [Abstract][Full Text] [Related]
40. S100A2 promoter-driven conditionally replicative adenovirus targets non-small-cell lung carcinoma.
Lee K; Yun ST; Yun CO; Ahn BY; Jo EC
Gene Ther; 2012 Oct; 19(10):967-77. PubMed ID: 22033466
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
